ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)

ChengDa Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	431.1	725.8	178.46	1,364	604.43	18.49
Trading Asset Securities	533.04	270.08	957.65	-	776.89	-
Cash & Short-Term Investments	964.14	995.88	1,136	1,364	1,381	18.49
Cash Growth	-11.60%	-12.34%	-16.70%	-1.26%	7369.47%	-60.67%
Accounts Receivable	141.78	111.33	97.75	126.68	111.13	93.08
Other Receivables	0.52	0.07	0.17	0.19	0.01	0.49
Receivables	142.3	111.39	97.92	126.87	111.14	93.56
Inventory	146.85	148.43	135.27	130.47	156.43	104.18
Prepaid Expenses	-	-	-	-	-	4.02
Other Current Assets	47.73	48.59	45.86	21.59	30.88	5.67
Total Current Assets	1,301	1,304	1,415	1,643	1,680	225.93
Property, Plant & Equipment	821.15	839	872.25	646.21	518.45	402.21
Long-Term Investments	66.71	68.48	7.41	30	30	-
Other Intangible Assets	37.37	37.16	36.51	33.85	34.58	39.83
Long-Term Deferred Tax Assets	13.98	13.34	8.06	4.29	4.23	2.79
Long-Term Deferred Charges	44.32	48.92	44.12	43.5	12.93	6.47
Other Long-Term Assets	47.65	38.68	52.94	54.6	41.95	6
Total Assets	2,332	2,350	2,436	2,455	2,322	683.23

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	142.47	164.63	189.23	139.89	77.82	57.83
Accrued Expenses	5.43	13.17	9.62	9.71	10.76	6.84
Short-Term Debt	-	-	-	-	-	54.06
Current Portion of Long-Term Debt	14.81	14.81	-	-	-	15
Current Income Taxes Payable	0.49	2.26	0.1	5.63	0.04	4.87
Current Unearned Revenue	4.89	3.35	2.79	11.87	6.18	7.82
Other Current Liabilities	3.69	4.74	5.03	4.43	4.74	1.37
Total Current Liabilities	171.77	202.97	206.76	171.53	99.54	147.78
Long-Term Debt	44.3	44.3	80.12	-	-	-
Long-Term Unearned Revenue	10.84	4.72	2.51	3.43	4.47	5.52
Long-Term Deferred Tax Liabilities	1.21	0.85	1.38	1.44	1.8	-
Total Liabilities	228.13	252.83	290.77	176.4	105.81	153.3

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	154.71	154.71	154.71	154.71	96.7	72.52
Additional Paid-In Capital	1,694	1,694	1,694	1,693	1,751	152.57
Retained Earnings	335.46	328.46	370.68	429.09	367.12	304.15
Treasury Stock	-57.07	-57.07	-57.07	-	-	-
Comprehensive Income & Other	-25.5	-25.5	-19.2	-	-	-
Total Common Equity	2,101	2,094	2,143	2,277	2,214	529.24
Minority Interest	2.63	2.61	2.64	1.8	1.68	0.68
Shareholders' Equity	2,104	2,097	2,146	2,279	2,216	529.93
Total Liabilities & Equity	2,332	2,350	2,436	2,455	2,322	683.23

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	59.11	59.11	80.12	-	-	69.06
Net Cash (Debt)	905.02	936.77	1,056	1,364	1,381	-50.56
Net Cash Growth	-9.72%	-11.29%	-22.58%	-1.26%	-	-
Net Cash Per Share	5.98	6.18	6.95	8.82	9.12	-0.44
Filing Date Shares Outstanding	151.47	151.47	151.47	154.71	154.71	116.04
Total Common Shares Outstanding	151.47	151.47	151.47	154.71	154.71	116.04
Working Capital	1,129	1,101	1,208	1,471	1,580	78.15
Book Value Per Share	13.87	13.83	14.15	14.72	14.31	4.56
Tangible Book Value	2,064	2,057	2,107	2,243	2,180	489.41
Tangible Book Value Per Share	13.63	13.58	13.91	14.50	14.09	4.22
Buildings	-	326.41	325.77	256.48	227.07	184.8
Machinery	-	703.54	701.73	430.36	328.86	313.05
Construction In Progress	-	108.19	101.46	179.17	153.53	70.7

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error